TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial

​TransCode Therapeutics, in partnership with Quantum Leap Healthcare Collaborative, has submitted an IND application amendment seeking approval from the US FDA for a planned Phase IIa trial of its lead colorectal cancer candidate, TTX-MC138.

The post TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us